Completed NA INTERVENTIONAL NCT00000662
A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease
Sponsor: Glaxo Wellcome
Conditions
HIV Infections
Interventions
Zidovudine
Updated 5 times since 2017 Last updated: Oct 27, 2016 Primary completion: May 31, 1993 Completion: May 31, 1993
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT00000662, this NA trial focuses on HIV Infections and remains completed. Sponsored by Glaxo Wellcome, it has been updated 5 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Glaxo Wellcome
- National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .